Mental Retardation, X-Linked 63
|
0.710 |
GeneticVariation
|
disease |
BEFREE |
A third MRX family (MRX68) is the result of mutation in the long chain fatty acid-CoA ligase 4 (FACL4) gene: proposal of a rapid enzymatic assay for screening mentally retarded patients.
|
12525535 |
2003 |
Mental Retardation, X-Linked 63
|
0.710 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation.
|
11889465 |
2002 |
Mental Retardation, X-Linked 63
|
0.710 |
GeneticVariation
|
disease |
UNIPROT |
FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation.
|
11889465 |
2002 |
Mental Retardation, X-Linked 63
|
0.710 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Mental Retardation, X-Linked 63
|
0.710 |
Biomarker
|
disease |
CTD_human |
|
|
|
Mental Retardation, X-Linked 63
|
0.710 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Alport Syndrome, Mental Retardation, Midface Hypoplasia, and Elliptocytosis
|
0.510 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation.
|
11889465 |
2002 |
Alport Syndrome, Mental Retardation, Midface Hypoplasia, and Elliptocytosis
|
0.510 |
Biomarker
|
disease |
BEFREE |
Identification and characterization of mouse orthologs of the AMMECR1 and FACL4 genes deleted in AMME syndrome: orthology of Xq22.3 and MmuXF1-F3.
|
10828604 |
2000 |
Alport Syndrome, Mental Retardation, Midface Hypoplasia, and Elliptocytosis
|
0.510 |
ChromosomalRearrangement
|
disease |
ORPHANET |
Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis: a new X linked contiguous gene deletion syndrome?
|
9598718 |
1998 |
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Then, immunohistochemical results demonstrated that the ACSL4 positive expression rate was 70.7% in HCC tissues.
|
28887439 |
2017 |
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, we showed that the expression levels of acyl-CoA synthetase long-chain family member 4 (ACSL4) were negatively associated with those of miR-205 in clinical HCC tissues.
|
24576478 |
2014 |
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
The acyl-CoA synthetase 4 (ACSL4) is increased in breast cancer, colon and hepatocellular carcinoma.
|
21085606 |
2010 |
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
CTD_human |
Discrimination of tumorigenic triazole conazoles from phenobarbital by transcriptional analyses of mouse liver gene expression.
|
19363144 |
2009 |
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
In this study, we detected the expression of FACL4 mRNA in 40 patients with hepatic carcinoma and its adjacent normal tissues by semi-quantitative RT-PCR.
|
18059177 |
2008 |
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
LHGDN |
FACL4 is involved in the HCC tumorigenesis and both cAMP and p38 MAPK pathways are associated with the regulation of FACL4 in HCC.
|
15849811 |
2005 |
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
FACL4 is involved in the HCC tumorigenesis and both cAMP and p38 MAPK pathways are associated with the regulation of FACL4 in HCC.
|
15849811 |
2005 |
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
We found that 14 out of 37 (37.8%) HCC expressed moderate to strong FACL4 immunostaining.
|
12824887 |
2003 |
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
LHGDN |
We found that 14 out of 37 (37.8%) HCC expressed moderate to strong FACL4 immunostaining.
|
12824887 |
2003 |
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Despite ACSL4 expression is upregulated progressively in CRC-like organoids, metformin is able to downregulate its expression, especially in the first two stages (I, II).
|
31339921 |
2019 |
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Here, we focus on functional differences and individual contribution of acyl coA synthetases (ACSL) isoforms to the previously described ACSL/stearoyl-CoA desaturase (ACSL1/ACSL4/SCD) metabolic network causing invasion and poor prognosis in colorectal cancer (CRC).
|
28894242 |
2017 |
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
High expression of ACSL4 predicted a worse prognosis in colorectal cancer, but predicted better prognosis in breast, brain and lung cancer.
|
27171439 |
2016 |
Mental Retardation, X-Linked 1
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, expression of an MRX-associated ACSL4 mutant form in a wild-type background led to the lesions in visual center, suggesting a dominant negative effect.
|
19617635 |
2009 |
Mental Retardation, X-Linked 1
|
0.330 |
Biomarker
|
disease |
BEFREE |
As skewed X-inactivation, an apparently constant feature in FACL4 carrier females was not observed in an obligate carrier belonging to the MRX family presented here, the PAK3 gene should be considered as the strongest candidate for this MRX locus.
|
12949969 |
2003 |
Mental Retardation, X-Linked 1
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
A third MRX family (MRX68) is the result of mutation in the long chain fatty acid-CoA ligase 4 (FACL4) gene: proposal of a rapid enzymatic assay for screening mentally retarded patients.
|
12525535 |
2003 |
Mental Retardation, X-Linked 1
|
0.330 |
GermlineCausalMutation
|
disease |
ORPHANET |
FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation.
|
11889465 |
2002 |